23andMe (NASDAQ:ME – Get Free Report) announced its earnings results on Tuesday. The company reported ($1.02) earnings per share for the quarter, Zacks reports. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%.
23andMe Stock Up 1.5 %
Shares of NASDAQ:ME traded up $0.05 during trading on Tuesday, hitting $3.40. The stock had a trading volume of 138,534 shares, compared to its average volume of 192,537. 23andMe has a 12 month low of $2.65 and a 12 month high of $16.52. The company has a market capitalization of $88.81 million, a PE ratio of -0.13 and a beta of 1.14. The firm’s fifty day moving average is $3.46 and its 200 day moving average is $5.41.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 23andMe in a research report on Saturday, January 18th.
23andMe Company Profile
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
See Also
- Five stocks we like better than 23andMe
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How to Use High Beta Stocks to Maximize Your Investing Profits
- What Does the Future Hold for Eli Lilly?
- The Most Important Warren Buffett Stock for Investors: His Own
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.
